Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Third Harmonic Bio has raised $3.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in January 2025.
Third Harmonic Bio's investors include General Atlantic, RA Capital Management, OrbiMed, RTW Investments, Ajax Health.
Third Harmonic Bio is headquartered in Cambridge, United States.
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.
Third Harmonic Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Third Harmonic Bio — Funding & Investors." VCBacked, January 22, 2025, https://www.vcbacked.co/company/third-harmonic-bio. Accessed August 11, 2026.
VCBacked. (2025). Third Harmonic Bio — Funding & Investors. Retrieved August 11, 2026, from https://www.vcbacked.co/company/third-harmonic-bio
{{cite web |title=Third Harmonic Bio — Funding & Investors |url=https://www.vcbacked.co/company/third-harmonic-bio |website=VCBacked |access-date=August 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated